Recent studies have focused on the convergence of glucagon-like peptide-1|GIP|glucagon receptor stimulant therapies and DA communication. While GCGR stimulators are commonly employed for managing type 2 diabetes mellitus, their potential consequences on motivation circuits, specifically governed by dopaminergic pathways, are gaining significant … Read More